Since 1976, the Food and Drug Administration has been involved activity in
the regulation of in vitro diagnostic devices. Regulation involves a series
of premarket and postmarket controls designed to assure that tests meet mi
nimum thresholds of performance and are labeled properly. The review progra
m for medical devices recently has undergone a variety of changes to produc
e more effective use of its regulatory tools.